Clinical Drugs used in MOA Use

conditions the treatment

Herpes Idoxuridine, Forscarnet- inhibits the
acyclovir pyrophosphate binding on viral
Foscarnet DNA polymerase
Antihepatits Interferons Interferon inducers turn on the Ribavirin- RSV and HCV
Entecavir synthesis of intrinsic factor for
Sofosbuvir- early innate immunity Entecavir- HEP-B
Hepatitis C
Ribavirin IFN- activate immune cells such Sofosbuvir- hep C
as NK and macrophages.

Sofosbuvir- inhibits RNA

polymerase used by hep C

Entecavir-blocks reverse
transcriptase

Ribavirin- M-RNA synthesis

inhibitor
Antinfluenza Amantidine, Amatadine and ramatadine- Z&O- for influenza A and
rimanditine inhibit replication of influenza A B
Zanamivir by blocking m2 proteininhibits
Osteltamivir viral coating and penetration A&R- influenza A

Z&O- inhibits neuraminidase

NRTI Zidovudine
NtRTs(nucleotide)
NNRTIs- nevirapine
Protease- Ritonavr
Fusion
 Given systematically of topically- When used systematically may be administered
Orally or IV

CONTRA- hypersensitivity , congestive HF, seizures and Renal disease and lactation

Side effects- Gi disturbances, burning & stinging- when topically applied.

Ribavirin- anemia
Foscarnet- renal insufficiency, electrolyte imabalance

Drug interaction- Etravirine- other protease inhibitors

Many inducers or inhibitors of liver enzymes-influenced by Cp450 Inhibitors-
erythromycin and clarithromycin